Publications by authors named "Arthur Bobin"
Article Synopsis
- CD38-targeting immunotherapy combined with lenalidomide and dexamethasone is the current best standard of care for newly diagnosed multiple myeloma patients who can't undergo transplants.
- A phase 3 study involving 270 patients tested the effectiveness of adding weekly bortezomib to this regimen, comparing the outcomes of the combination (Isa-VRd) against the standard (IsaRd).
- Results showed a significantly higher rate of minimal residual disease negativity at 18 months and better response rates in the Isa-VRd group, suggesting it could become the new standard of care for these patients.
Article Synopsis
- Posterior reversible encephalopathy syndrome (PRES) is a rare condition noted in myeloma patients, often linked to chemotherapy, particularly proteasome inhibitors and stem cell transplants.
- A study analyzed three myeloma patients with PRES alongside 13 other published cases, primarily affecting women, highlighting risk factors like hypertension, infection, or renal failure.
- Common symptoms include headache and seizures, but most patients recover quickly and don’t experience relapses, suggesting that better blood pressure management may help prevent PRES in these individuals.
Article Synopsis
- F-FDG PET/CT is important for diagnosing and monitoring Hairy Cell Leukemia (HCL), especially in atypical cases with bone involvement.
- The study highlighted two patients with BRAF mutation who had significant bone lesions and limited bone marrow infiltration, demonstrating the utility of F-FDG PET/CT.
- The authors emphasize integrating F-FDG PET/CT into standard HCL management to improve patient outcomes and detect less common manifestations.
Article Synopsis
- Myeloproliferative neoplasms in the blastic phase (MPN-BP) have a poor prognosis, but a study on five patients showed promising results with a new treatment combining azacytidine, venetoclax, and ruxolitinib.* -
- The patients, aged between 72 and 84, had an overall response rate of 80%, with 40% achieving complete remission during a median follow-up of 10 months.* -
- There were no unexpected toxicities from the treatment, and the patients experienced an improved quality of life, with a median overall survival of 13.4 months.*
The treatment of multiple myeloma (MM) has greatly evolved these past few years. Recent advances in therapeutics have largely benefited elderly patients now renamed "non-transplant-eligible" (NTE) patients. Since the 1960s, and for several decades, chemotherapy was the only treatment for MM.
View Article and Find Full Text PDFThe recent history of multiple myeloma has been marked by tremendous advances in the treatments available, which have ultimately improved the patients' survival. Immune-based therapies, starting with the emergence of anti-CD38 monoclonal antibodies, whose impact is seen across all groups of patients, are probably the greatest evolution in the field of myeloma so far. Building on the efficacy of immunotherapy, "modern" immunological treatments such as CAR-T cells or bispecific antibodies are being developed.
View Article and Find Full Text PDFNovel treatments are needed to address the lack of options for patients with relapsed or refractory multiple myeloma. Even though immunotherapy-based treatments have revolutionized the field in recent years, offering new opportunities for patients, there is still no curative therapy. Thus, non-immunologic agents, which have proven effective for decades, are still central to the treatment of multiple myeloma, especially for advanced disease.
View Article and Find Full Text PDFArticle Synopsis
- - Smoldering multiple myeloma (SMM) is a type of asymptomatic plasma cell disorder with specific criteria, including high levels of monoclonal protein and a significant percentage of plasma cells in the bone marrow, but no symptoms indicative of active disease.
- - There's a push to redefine high-risk SMM to identify patients who are more likely to progress to active multiple myeloma (MM) within two years, using models like the 20/2/20 and the IMWG risk model with additional genetic factors.
- - The ongoing debate focuses on whether to adopt aggressive treatment strategies aimed at curing the disease or to pursue a more cautious approach that enhances immune function while monitoring the condition, challenging the traditional "watch-and-w
Article Synopsis
- Primary or secondary immune deficiency (ID) is a rare risk factor for developing Waldenström macroglobulinemia (WM), with a study showing 3.6% of WM patients had a history of ID.
- Among these patients, half required treatment for WM within a median of 1.5 years after diagnosis, while the progression to active disease typically occurred 8 years after ID onset.
- The research suggests that while WM can arise from ID, the outcomes are generally not poor, with many cases remaining indolent despite the associated immune deficiency.
The multiple myeloma (MM) non transplant eligible (NTE) population is growing in line with the aging of the population in Western countries. Historically, this population has been known for having a greater risk of treatment related toxicity, and therefore drug development was slow and rather oriented towards the improvement of safety profile than the optimization of disease control. However, NTE MM patients, at least for the fit/non frail patients in recent years, seemed to have benefited more from a less palliative care to improve the depth of response and then prolong survival.
View Article and Find Full Text PDFThe survival rate of multiple myeloma (MM) patients has drastically increased recently as a result of the wide treatment options now available. Younger patients truly benefit from these innovations as they can support more intensive treatment, such as autologous stem cell transplant or multiple drug association (triplet, quadruplet). The emergence of immunotherapy allowed new combinations principally based on monoclonal anti-CD38 antibodies for these patients.
View Article and Find Full Text PDFMobilization of peripheral blood stem cells (PBSC) can be performed using plerixafor, which is expensive, or high-dose cyclophosphamide (HDCy). We hypothesized that the overall cost of mobilization with plerixafor might not be greater if the cost of complication management was considered. We performed a cost analysis of these two strategies.
View Article and Find Full Text PDFAs the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these patients remains a real challenge especially because of a marked heterogeneity in the population and an increased susceptibility to treatment toxicity. Indeed, the balance between efficacy and safety must be considered at all time throughout the treatment history for these patients.
View Article and Find Full Text PDFBackground: Streptococcus pneumoniae infection causes morbidity and mortality in multiple myeloma patients. Pneumococcal vaccination is commonly given to immunocompromised myeloma patients; however response data are sparse. Here, we present longitudinal response data to pneumococcal vaccination in multiple myeloma patients.
View Article and Find Full Text PDFArticle Synopsis
- A study reports on a patient with AML-M2 who has a unique NUP98-LEDGF gene fusion, showing three different fusion mRNAs due to alternative splicing.
- High-throughput sequencing identified additional mutations (IDH1, SRSF2, WT1) in this patient, and a real-time PCR method was developed for monitoring NUP98-LEDGF mRNA levels.
- Following a poor response to traditional chemotherapy, the patient underwent stem cell transplantation and subsequent azacitidine treatment, ultimately achieving complete molecular remission 25 months post-transplant.
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.
Oncotarget
May 2018
Purpose: Multiple myeloma (MM) remains an incurable disease as tumor cells ultimately resist to all available drugs. Homing of tumor cells to the bone marrow microenvironment, involving especially the CXCR4/SDF-1 axis, allows them to survive, proliferate and resist to therapy. F50067, a humanized anti-CXCR4 IgG1 antibody, has promising preclinical activity in MM.
View Article and Find Full Text PDF